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The risk of developing neurodegenerative diseases increases with age. Although many of the molecular path-
ways regulating proteotoxic stress and longevity are well characterized, their contribution to disease suscep-
tibility remains unclear. In this study, we describe a new Caenorhabditis elegans model of Machado–Joseph
disease pathogenesis. Pan-neuronal expression of mutant ATXN3 leads to a polyQ-length dependent, neuron
subtype-specific aggregation and neuronal dysfunction. Analysis of different neurons revealed a pattern of
dorsal nerve cord and sensory neuron susceptibility to mutant ataxin-3 that was distinct from the aggregation
and toxicity profiles of polyQ-alone proteins. This reveals that the sequences flanking the polyQ-stretch in
ATXN3 have a dominant influence on cell-intrinsic neuronal factors that modulate polyQ-mediated pathogen-
esis. Aging influences the ATXN3 phenotypes which can be suppressed by the downregulation of the insulin/
insulin growth factor-1-like signaling pathway and activation of heat shock factor-1.
INTRODUCTION
Machado–Joseph disease (MJD) (or spinocerebellar ataxia
type 3) is the most common dominantly inherited ataxia
worldwide (1,2). This adult-onset neurodegenerative disorder
is characterized by ataxia, ophthalmoplegia and pyramidal
signs, associated in variable degree with dystonia, spasticity,
peripheral neuropathy and amyotrophy (3), but with no cogni-
tive decline. Pathologically, the disorder is associated with the
degeneration of the deep nuclei of the cerebellum, pontine and
subthalamic nuclei, substantia nigra and spinocerebellar
nuclei. Similar to Huntington’s disease (HD), spinobulbar
muscular atrophy and other ataxias, MJD is caused by a trans-
lated unstable CAG trinucleotide-repeat expansion. The
resulting polyglutamine (polyQ) expansions render the
affected proteins susceptible to abnormal conformations that
promote the formation of neuronal inclusions (4–6). Despite
this unifying feature, specific populations of neurons are
affected in different polyQ disorders, suggesting that protein
domains outside the polyQ tract contribute to the pathological
signature of each disease. In MJD, it is known that this neuron-
specific susceptibility is not the result of the mutant ataxin-3
(ATXN3) expression pattern, as this protein, like all the
other polyQ-containing proteins, is widely expressed from
very early stages of development (7,8). ATXN3 is a small
protein that contains a cysteine protease-like domain, the Jose-
phin domain and two or three ubiquitin-interacting motifs
(UIMs). Among the polyQ-containing proteins, ATXN3 is
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unique because it has been implicated in cellular protein
degradation pathways, through its deubiquitylase (9–12) and
deneddylaseQ1 (13) activities.
The mean age at onset of MJD is 37 years (14) and corre-
lates significantly with the number of CAG/polyQ repeats,
with earlier onset in individuals with larger repeat sizes.
However, there is considerable individual variation of age at
onset within a given repeat-length range (reviewed in 15, high-
lighting the role of other genetic and environmental factors.
Correlative evidence suggests aging as a major risk factor
for the development of many neurodegenerative diseases
(16). Typically, individuals that carry neurodegeneration-
linked mutations develop the disease during their fifth
decade, whereas sporadic cases appear during the seventh
decade or later (17). It is still unclear why distinct neurodegen-
erative diseases occur late in life with overlapping temporal
inceptions. One likely possibility is that the aging process
interferes with the cellular proteostasis machinery, enabling
misfolding, aggregation and initiating neurodegeneration
(18,19). Recent studies point to the insulin/insulin growth
factor (IGF)-1-like signaling (IIS) pathway, facilitated by
heat shock factor-1 (HSF-1), as major candidates that link
aging, proteotoxicity and neurodegenerative diseases (20–22).
MJD pathogenesis has been recapitulated in vivo in a variety
of invertebrate and rodent model systems (23–29). Caenor-
habditis elegans has been successfully used to model neurode-
generation in vivo, mainly due to the conservation of basic
cellular mechanisms, such as those coupled with neuronal sig-
naling, cell death/survival and the maintenance of proteostasis
and aging. The morphology of all 302 neurons has been
defined by electron microscopy, and much is known about
their synaptic connectivity and functional properties (30,31).
Despite having relatively few neurons, C. elegans exhibit
complex behaviors that can be assayed to monitor neuronal
dysfunction, which can be combined with biophysical assays
to examine protein solubility in neurons of interest (32). Pre-
vious studies using C. elegans to investigate polyQ pathology,
in subsets of neurons or in body-wall muscle cells, have found
a polyQ length-dependent aggregation and toxicity (33–36).
Recent studies have introduced the possibility of studying
the impact of the expression of a single species of a misfolded
polyQ protein on the C. elegans nervous system and its toxic
behavioral outcome. These studies have shown neuronal
subtype-specific vulnerability to the expression of polyQ seg-
ments at the threshold Q-length for aggregation and neuronal
dysfunction (32).
Here, we have established a new C. elegans model of MJD
in which ataxin-3 was expressed throughout the nervous
system. The comparison of these ATXN3 models with the pre-
viously characterized polyQ-alone models (32) should also
shed light on the modulatory effects of protein context in
pathogenesis. In our model, the expression of both full-length
and truncated forms of ataxin-3, with different Q-lengths,
results in a consistent pattern of neuronal cell-type-specific
aggregation, with the ventral and dorsal nerve-cord neurons
being highly affected, while some lateral interneuron cell
bodies are resistant. Certain sensory processes in the head
contain aggregated foci, but only when the polyQ stretch is
within the ATXN3 protein-flanking sequences, and not when
expressed alone. We have also studied the impact of aging
and of reprogramming animals’ survival in our model, and
we found that reducing IIS and activating HSF-1 pathways
(genetically or pharmacologically) reduced pathogenesis, sup-
porting the mechanistic links between the aging process and
neuronal toxic-protein aggregation, which are common hall-
marks of many neurodegenerative disorders.
RESULTS
Expression of full-length ataxin-3 in live neuronal cells
causes polyQ length-dependent aggregation
The pathogenesis of ATXN3 was studied in transgenic
C. elegans strains expressing human wild-type (WT) or patho-
logical full-length ATXN3 throughout the nervous system.
Normal-length (q14) and mutant (q75 and q130) ATXN3
were tagged at the C-terminus with YFP and expressed in
neuronal cells under the control of the promoter of the
F25B3.3 Q2gene (Supplementary Material, Fig. S1A). This
gene encodes a C. elegans ortholog of the Ca2+-regulated
Ras nucleotide exchange factor, RasGRP, that is expressed
widely throughout the nervous system. The F25B3.3 gene pro-
moter (PF25B3.3) becomes active in the comma Q3stage of embry-
ogenesis and expression persists after the terminal division of
neurons (37). Expression of YFP-alone (Q0) and Q(n)::YFP
(Qn, n ¼ number of glutamines) under the control of the
F25B3.3 promoter occurs throughout the nervous system
(32), demonstrating that PF25B3.3 is an appropriate tool to
evaluate the response of different neurons to pathological
ATXN3.
We verified that the levels of WT or mutant ATXN3 mRNA
and protein expressed in transgenic lines were equivalent and
at the expected molecular size (Supplementary Material,
Fig. S2A and B). Only transgenic lines expressing levels of
ATXN3 mutant proteins similar to or lower than the WT
ATXN3 were selected for further study, as higher expression
levels could influence aggregation and toxicity (Supplemen-
tary Material, Fig. S2A).
Analysis of the transgenic animals expressing ATXN3 pro-
teins revealed that pan-neuronal expression of WT AT3q14
resulted in diffuse neuronal distribution (Fig. 1, panel 1),
similar to that observed for Q0 animals (32). Uniform
diffuse expression of AT3q14 was detected in the nucleus
and the cytoplasm of neuronal cell bodies and processes
along the entire length of the ventral nerve cord (VNC)
(Fig. 1, panel 1, thin arrow) and the dorsal nerve cord
(DNC) (Fig. 1, panel 1, thick arrow). Likewise, animals
expressing AT3q75 also showed diffuse YFP fluorescence,
similar to WT AT3q14 animals in the cell bodies and pro-
cesses throughout the nervous system (Fig. 1, panel 2).
However, AT3q130 animals show heterogeneity with discrete
foci detected in some neurons and diffuse protein in other
neurons. Foci formation was clearly evident in both the
nucleus and the cytoplasm of cell bodies and in neuronal pro-
cesses of VNC (Fig. 1, panel 3, thin arrow and Supplementary
Material, Fig. S3A, C and D, respectively), DNC (Fig. 1, panel
3, thick arrow), commissures (Supplementary Material,
Fig. S3B) and certain nerve ring cells (Fig. 1, panel 3, arrow
head). AT3q130 foci were observed in the first larval stage
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(L1) (Supplementary Material, Fig. S4A) and persisted
throughout the lifespan.
We further characterized the AT3q130 foci by dynamic
imaging and fluorescence recovery after photobleaching
(FRAP) techniques to distinguish between foci of soluble or
aggregated protein. As shown in Figure 2, the recovery rate
after photobleaching observed for WT ATXN3 (AT3q14)
and AT3q75 proteins in neurons was indistinguishable from
the soluble Q0 control. In contrast, the AT3q130 foci exhibited
only partial recovery (30% recovery over 150 s) [AT3q130
(A)], consistent with the properties of an immobile aggregated
species and similar to that observed for the well-characterized
Q67::YFP (Q67) aggregates (Fig. 2A and B) (32). We there-
fore employed the FRAP analysis to examine the foci in dis-
crete neurons located in the head and tail of the animals, as
well as in the VNC (adjoining the vulva) and DNC (opposing
the vulva). The diffuse AT3q130 expressed in certain VNC,
DNC and lateral neurons by comparison showed rapid
FRAP recovery indicating that proteins in these neurons
[AT3q130(S)] were soluble. Consistent with this, all soluble
proteins analyzed by FRAP showed significant recovery
rates at the first time point measured (2.27 s) (Fig. 2).
Phenotypic characterization of ATXN3-expressing animals
showed that AT3q14 or AT3q75 animals were similar to
WT N2 animals for lifespan and movement, whereas
AT3q130 animals were lethargic and had slightly reduced life-
span (Supplementary Material, Fig. S5). Nevertheless,
AT3q130 animals developed to adulthood and had similar
brood sizes (data not shown).
Expression of a C-terminal cleavage fragment of ataxin-3
forms polyQ length-dependent aggregates in C. elegans
neurons
A common feature of many proteins associated with neurode-
generative disease is proteolytic fragmentation. Likewise,
there is evidence to support the proteolysis of ATXN3 in
mammalian cells, transgenic mice and MJD brain tissue
(25,38–40). To gain additional insight into the biochemical
and cell biological properties of truncated ATXN3, we
expressed a C-terminal fragment of ATXN3 lacking the
amino terminal 257 amino acids of the protein (257cAT3)
and retaining the polyQ expansion (q14, q75, q80 and q128)
and the UIM3 domain of ATXN3 (Supplementary Material,
Fig. S1B) (41). For each of these lines, the neuronal
expression of 257cAT3 was at the expected molecular size
for mRNA and protein, and at comparable or lower levels
than WT controls, indicating that this C-terminal ATXN3
fragment is stably expressed (Supplementary Material, Fig.
S2A and B).
In young adult animals (day 4, post-hatching), expression of
257cAT3q14 resulted in a diffuse neuronal pattern, as
observed for full-length AT3q14 and YFP-alone expressing
animals. However, animals expressing 128 polyQs
(257cAT3q128) formed discrete foci throughout different
cells of the nervous system (Fig. 3A). These animals were
smaller in size and more lethargic than AT3q130 expressing
animals and WT controls, yet they developed to the adult
stage and had progeny, delayed by 1 day when compared
with 257cAT3q14 animals. We then examined transgenic
lines expressing intermediate polyQ lengths of 257cAT3q75
and 257cAT3q80 and observed the appearance of some
neurons with discrete puncta, whereas in other cells only
diffuse protein was detected (Fig. 3A). Protein aggregates
were detected in day 2 animals (Supplementary Material,
Fig. S4B). The appearance of foci in 257cAT3q75, but not
in full-length AT3q75, reveals that the C-terminal truncated
protein is more aggregation-prone. Animals expressing
257cAT3q75/80 also exhibited similar rates of development
to adulthood as animals expressing full-length AT3q14/75
and WT truncated ATXN3 (257cAT3q14) (data not shown).
The biophysical properties of 257cAT3q75 were compared
with 257cAT3q14 using FRAP analysis and showed that
257cAT3q14 exhibited rapid recovery after photobleaching
(Fig. 3B), whereas foci in 257cAT3q75 neurons did not
recover [Fig. 3B, 257cAT3q75(A)]. We observed heterogen-
eity among 257cAT3q75 expressing neurons; FRAP analysis
of multiple VNC neurons showed differences in
257cAT3q75 protein solubility, ranging from completely
soluble [Fig. 3B, 257cAT3q75(S)] to completely insoluble
[Fig. 3B, 257cAT3q75(A)]. Molecular heterogeneity was
also observed in neurons of the head and tail ganglia of the
same animals and from independent transgenic lines (data
not shown). By comparison, 257cAT3q128 foci formed
immobile aggregates in all neurons tested (Fig. 3B). These
results demonstrate that the presence of soluble or aggregated
C-terminal ATXN3 protein can vary among different neurons
and that this aggregation phenotype is strongly influenced by
polyQ length.
Figure 1. Pan-neuronal expression of full-length ATXN3 in C. elegans causes
polyQ length-dependent changes in protein distribution. Expression of
AT3q14 and AT3q75 proteins displayed a smooth and diffuse distribution
pattern (left and middle panels, respectively), whereas AT3q130 proteins are
found in discrete foci in certain neurons and are soluble in others (right
panel). In the left panel, AT3q14 protein expression could be visualized in
cell bodies (thin arrow) and in neuronal processes (thick arrow). In panel 3,
the distribution of AT3q130 proteins was strikingly different: foci formation
was clearly evident in VNC (thin arrow), DNC (thick arrow) and in certain
cells of the circumpharyngeal nerve ring (arrow head). All animals depicted
are young adults (4 days post-hatching). Scale bar, 100 mm. White boxes indi-
cate magnified regions. The images were obtained using a Zeiss LSM 510 con-
focal microscopeQ8 .
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In summary, the aggregation profiles in C. elegans neurons
for the C-terminal ATXN3 proteins were similar to that
observed for the full-length ATXN3 model. The transition
from soluble to aggregate states was observed only with the
mutant polyQ expansion and exhibited neuron-to-neuron vari-
ation. Sequence context also has a role because the expression
of 75Qs caused aggregation only in the context of C-terminal
ataxin-3 and not of the full-length ATXN3 protein.
Aggregation of mutant ataxin-3 in specific neuronal cells
is not stochastic
Previous studies on aggregation of Q40-alone proteins in the
nervous system of C. elegans showed that aggregation is
cell-type-specific and not stochastic, suggesting that polyQ
solubility is modulated by the intrinsic properties of the neur-
onal cell environment (32).
We examined the properties of AT3q130 and 257cAT3q75
in specific neurons of at least two independent transgenic
lines. Using the FRAP analysis, both mutant ATXN3 proteins
were detected only in a soluble state in HSN Q4neurons
(Fig. 4A), whereas in the VNC and DNC neurons both
soluble and immobile AT3q130 and 257cAT3q75 were
detected (Figs 2 and 3B). Protein aggregates were also
detected in certain neuronal processes in the head (Fig. 4B,
square), but this occurred only in animals expressing mutant
ATXN3-flanking sequences, and not in animals expressing
polyQ-alone tracts (32). Many of these processes correspond
to sensory neurons. To further examine the expression of
mutant ATXN3 in sensory neurons, we co-expressed
AT3q130 with mCherry under the regulation of the CHE-13
promoter (PCHE-13::mCherry) that is expressed in nearly all
ciliated sensory neurons. Aggregates were not detected in
the cell bodies of ASJ, ASI, ADL, ASK, ASE and ASH Q4
neurons (data not shown). However, in 88% of the animals
analyzed (N ¼ 50), CHE-13-positive processes contained
aggregated mutant ATXN3 proteins (Fig. 4C). Despite the
occasional appearance of aggregates, all six dye-stainable che-
mosensory amphid neurons in the anterior region (as well as
the phasmid tail neurons) exhibited normal DiD staining
(data not shown), suggesting that they were functional and
not undergoing degeneration.
To confirm that this aggregation pattern was specific rather
than stochastic, we co-expressed Q40 (fused to CFP) (32)
together with full-length ataxin-3 with polyQ75 (AT3q75)
fused to YFP. Whereas AT3q75 does not aggregate in
C. elegans neuronal cells, co-expression with Q40 resulted in
aggregate formation in certain VNC neurons. Analysis of
these double-transgenic animals revealed that AT3q75 and
Q40 proteins had a synergistic effect in the C. elegans nervous
Figure 2. Expression of full-length ATXN3 in live neuronal cells causes
polyQ length-dependent aggregation. For FRAP of neurons expressing Q0
proteins, the RFI of the photobleached area (red box), recovers rapidly
(A and B ‘Q0’). Similar results were obtained in neurons expressing WT
AT3q14 and AT3q75 (A and B ‘AT3q14’ and ‘AT3q75’), indicating the
presence of soluble proteins, whereas bleached Q67 foci did not recover
(A and B ‘Q67’). Q67 proteins are insoluble and were used as an aggregated
experimental control. FRAP experiments on AT3q130 animals revealed that
some areas display fast FRAP [A and B ‘AT3q130 (S)’], whereas others, con-
taining protein foci, did not recover, indicating the presence of a highly
immobile aggregated protein [A and B ‘AT3q130 (A)’]. Quantification
(B) was performed in six or more experiments and is represented as the
mean+SEM. Scale bar, 5 mm. The images and FRAP measures were
obtained using a Zeiss LSM 510 confocal microscope.
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system, as we observed the formation of protein foci in certain
processes in the head (Fig. 4D, arrows), but not when either
Q40 or AT3q75 proteins were expressed alone, nor when WT
AT3q14 and Q40 (Supplementary Material, Fig. S6A) or
Q40::CFP and Q40YFP proteins were co-expressed (Sup-
plementary Material, Fig. S6B). Figure 4E shows the quantifi-
cation of aggregates (42) of the processes of AT3q75;Q40
animals head (∗P, 0.05). Even in this example of polyQ
synergy, aggregates were not detected in the HSN neurons.
These data support a neuron-subtype-specific aggregation
pattern in our ATXN3 pathogenesis model that reflects the con-
sequences of ataxin-3 protein context and neuronal cell intrinsic
factors.
Ataxin-3 aggregation is highly associated with motor
dysfunction
To test whether ataxin-3 expression results in neuronal dys-
function, we performed a series of behavioral assays. Inner-
vation of muscle cells requires more than 60 neurons in
C. elegans and neuronal dysfunction often results in reduced
motility due to a lack of coordination (31,43). In addition to
the formation of protein aggregates, expression of mutant
ATXN3 (AT3q130) resulted in reduced movement compared
with age-matched WT ATXN3-expressing animals
(Supplementary Material, Video S1). The motility of the
ATXN3-expressing animals was quantified by scoring
animals that remained within a 1 cm circle after being trans-
ferred into the centre of a freshly seeded plate (44). Animals
expressing full-length WT AT3q14 and AT3q75 proteins did
not exhibit any impairment at adulthood (day 4), whereas
AT3q130 animals exhibited a significant reduction in motility
(∗P , 0.05) (Fig. 5). In animals expressing the truncated
ATXN3, 257cAT3, the effect on motility was even more
severe, and we observed a polyQ length-dependent motor dys-
function that correlated with aggregation (Figs 3 and 5). For
comparison, we also assessed animals expressing polyQ-alone,
and in accordance with what was observed previously, animals
expressing Q40 and Q67 had dramatic deficits in motility (32)
(Fig. 5). Because protein aggregates were detected in sensory
processes in the head, we tested for effects on chemosensation
(45) in animals expressing full-length and truncated ATXN3.
AT3q130 animals showed a slight reduction in chemotaxis
index (Ci) to isoamyl alcohol (1021 dilution) relative to WT
animals (Supplementary Material, Fig. S7), and
257cAT3q75, but not Q40 animals showed a significant
decrease in Ci (Supplementary Material, Fig. S7; ∗P , 0.05).
Taken together, these results suggest that the presence of
aggregates is associated with neuronal dysfunction in our
C. elegans model of ATXN3 pathogenesis. Moreover, the
Figure 3. Expression of C-terminal ataxin-3 forms polyQ length-dependent aggregates in C. elegans neurons. Flattened z-stacks of C. elegans heads revealed that
the expression of a range of polyQ lengths within the context of C-terminal ATXN3 flanking regions caused polyQ length-dependent aggregation (A and B). We
observed that 257cAT3q14 proteins displayed a smooth and diffuse distribution pattern, whereas 257cAT3q128 proteins were distributed into discrete foci. The
257cAT3q75 and 257cAT3q80 animals contained protein foci in certain neurons and soluble protein in others (A). Neurons expressing Q0 and 257cAT3q14
proteins recovered rapidly after photobleaching (B, ‘Q0’ and ‘257cAT3q14’), indicating the presence of soluble proteins. Bleached Q67 and 257cAT3q128
foci did not recover (B, ‘Q67’ and ‘257cAT3q128’). FRAP experiments on 257cAT3q75 animals revealed that some neurons displayed fast FRAP
[B, ‘257cAT3q75 (S)’] whereas others, containing protein foci, did not recover, indicating the presence of insoluble protein (B- ‘257cAT3q75 (A)’). Quantifi-
cation (B) was performed in eight or more experiments and is represented as the mean+SEM. All animals depicted are young adults (4 days post-hatching).
Scale bar, 50 mm. The images and FRAP measures were obtained using a Zeiss LSM 510 confocal microscope.
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expression of full-length AT3q130, C-terminal 257cAT3q80
and Q40 proteins caused the same level of toxicity (Fig. 5,
dashed line) highlighting the modulatory effects of flanking
protein regions in polyQ-containing proteins on motor dys-
function.
Age-dependent changes in mutant ataxin-3 aggregation
dynamics
The risk of developing a neurodegenerative disease increases
with age. Previous work has shown that polyQ aggregation
progresses in an age-dependent manner in muscle cells (36)
and in specific neurons (23,33). Therefore, we analyzed the
aggregation profile of ATXN3 transgenic animals during
aging. In AT3q130 animals, aggregation (initially detected at
day 1 post-hatching; Supplementary Material, Fig. S4) was
observed to increase during aging. This was particularly
clear in the anterior and ventral ganglia neurons in the nerve
ring (Fig. 6A). Heterogeneity in protein solubility and aggre-
gation persisted in the nerve cords during aging (data not
shown). Of the C-terminal fragments, 257cAT3q75- and
257cAT3q80-expressing animals showed age-dependent
aggregation (Fig. 6B). For both the full-length and C-terminal
ATXN3 proteins, aggregates were not detected in HSN
neurons of old animals. In comparison, AT3q75 did not
form aggregates during aging; however in some animals, we
observed large foci in day 10 of adulthood that corresponded
to a soluble protein (Fig. 6A, arrows) by FRAP analysis
(data not shown). Likewise, animals expressing WT (full-
length and truncated) ATXN3 did not form aggregates
during their lifespan. These results reveal that aging contrib-
utes to the onset and progression of ATXN3 polyQ aggrega-
tion, as has been reported for other model systems and
humans. However, our ability to monitor the aggregation phe-
notypes across multiple subclasses of neurons reveals differen-
tial susceptibility, with certain neurons such as the HSN more
resistant to aggregation compared with the VNC and DNC
neurons that are more sensitive to aggregation during aging.
IIS and HSF-1 pathways modify mutant ataxin-3-mediated
pathogenesis in C. elegans
Aggregation and toxicity of polyQ are strongly affected by the
IIS pathway and the activities of transcription factors DAF-16
and HSF-1 (21,36). To test whether ataxin-3 proteotoxicity is
influenced by these pathways, we examined the effects of
Figure 4. The aggregation pattern of mutant ATXN3 in specific neuronal cells is not stochastic. FRAP analysis of the HSN neuron on the left side (A) of
AT3q130 and 257cAT3q75 animals revealed that both proteins were consistently soluble (at least 80% FRAP) in the two or three independent lines that
were tested for each genotype. Quantification was performed in 10 or more experiments and is represented as the mean+SEM. (A) Flattened z-series of
C. elegans heads expressing mutant ataxin-3 proteins showed the presence of aggregates in certain neuronal processes [a 257cAT3q75 day 4 animal is
shown as an example in (B)]. White box indicates the magnified region. The aggregates co-localized with mCherry proteins that were expressed under the regu-
lation of the CHE-13 promoter (C). (C) depicts a z-stack (first panel) and a single slice (second panel), showing one aggregate co-localizing with the sensory
neuron process (red) (C, arrows). Flattened z-stacks of day 4 animals co-expressing AT3q75::YFP with Q40::CFP proteins, showing protein aggregates in certain
sensory processes of the head (D, arrows). The first panel shows the head of one animal expressing AT3q75 proteins; the second panel shows one animal expres-
sing Q40 proteins; third and fourth panels show the expression of AT3q75 or Q40 proteins of a AT3q75; Q40 animal; fifth panel displays a merged image.
(E) Quantification of the aggregates of the sensory processes of AT3q75;Q40 in comparison with AT3q14;Q40 animals (Supplementary Material, Fig. S6A).
In all images, scale bar ¼ 50 mm. The images were obtained using either an Olympus (A and C) or a Zeiss LSM 510 (B and D) confocal microscope.
FRAP measurements (A) were performed using the Olympus FV100 confocal.
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mutations in the insulin/IGF-1 receptor DAF-2 (46) on the
properties of AT3q130. In the background of the
daf-2(e1370) mutation, which confers a long-lived phenotype,
animals expressing AT3q130 (daf-2; AT3q130) showed a ten-
dency for decreased aggregation (Fig. 7A, squares, and F) with
foci barely detected. Likewise, motor function improved
2-fold (from 46.8 to 25.6%) in daf-2; AT3q130 animals
(Fig. 7G). Similar results were obtained with a
loss-of-function allele (hx546) in age-1 (47) that restored the
motility of AT3q130 animals from 40% reduction to 14.7%
(Fig. 7G). These results support the role of DAF-16 (48,49)
in protection against proteotoxicity. Consistent with this, the
daf-16 null (mu86) allele had a major effect on motor dysfunc-
tion in C. elegans daf-16; AT3q130 animals (from 40.1 to
74.4%) (Fig. 7H). We further demonstrated a protective role
for DAF-16 with valproic acid (VA) that stimulates the trans-
location of DAF-16 into the nucleus (50). VA partially rescued
the motor dysfunction induced by AT3q130 expression, at day
10 of adulthood (a reduction in motility impairment from 71.8
to 37.9%), an effect that was suppressed in daf-16(mu86)
mutants, suggesting that the mode of action for the rescue of
mutant-ATXN3 toxicity was in part through the IIS pathway
(Fig. 8A). Moreover, day 10 AT3q130 VA-treated animals
showed the same locomotion defect as day 4 untreated
animals. In contrast to the significant phenotype effect, and
as for daf-16(mu86) mutation (Fig. 7D and F), VA treatment
had only a mild effect on AT3q130 protein aggregation
(Fig. 8B), which was not due to changes in AT3q130
protein levels (Supplementary Material, Fig. S8). In all
cases, the effects of mutations in DAF-2, AGE-1 and
DAF-16 Q2genes in ATXN3 pathogenesis were not due to
effects on AT3q130 expression (Supplementary Material,
Fig. S9).
Recent studies have also implicated HSF-1 in lifespan
extension caused by reduced DAF-2 activity, with cross-talk
between the DAF-2 and HSF-1 pathways (20,21). Therefore,
we tested the effect of the hsf-1(sy441) (51) mutation on
ATXN3 pathogenesis. The loss of hsf-1 was deleterious to
transgenic animals, with mutant ataxin-3 proteins becoming
fully aggregated in neuronal cells and detected in early
embryos (Fig. 7E, arrow). Moreover, hsf-1; AT3q130
animals were completely paralyzed at day 4 (Fig. 7H). Con-
sistent with these results, exposure of AT3q130 animals to
the small-molecule Hsp90 inhibitor, 17-DMAG Q4, that induces
the heat shock response (HSR), improved motility when com-
pared with untreated controls (Fig. 8C). The effect of
17-DMAG was dependent on hsf-1 (Fig. 8C). Treatment
with 17-DMAG also reduced the aggregation of AT3q130
animals (Fig. 8D), with no effect on ATXN3 steady-state
Figure 5. Increases in polyQ-length associated with neuronal dysfunction in ataxin-3 C. elegans model. Percentage of locomotion defective of age-synchronized
young adult animals (day 4, post-hatching). There was a polyQ length-dependent increase in motor dysfunction in both full-length and C-terminal
ATXN3-expressing animals. Q(n) lines were used as an experimental control. ATXN3 protein-flanking sequences modulate the animals’ motor phenotype.
Dashed line shows that the expression of AT3q130, 257cAT3q80 and Q40 proteins in all neurons caused similar percentages of defect in locomotion. Data
are the mean+SD, at least 150 animals per data point. Student’s t-test, ∗P, 0.05.
Figure 6. Influence of age on mutant ATXN3 aggregation dynamics. Flattened
z-stacks of C. elegans heads of days 4 and 10 animals (post-hatching). The
aggregation phenotype of AT3q130 (A) and 257cAT3q75/80 (B) animals
was aggravated with age. The increase in aggregation was particularly
evident in the circumpharyngeal nerve ring of the animals. Arrows in the
AT3q75 panel indicate protein foci that did not correspond to aggregates, as
assessed by FRAP (data not shown). Scale bar, 50 mm. All pictures were
obtained using a Zeiss LSM 510 confocal microscope.
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protein levels (Supplementary Material, Fig. S8). 17-DMAG
treatment still decreased the locomotion impairment of
AT3q130 animals in the absence of DAF-16 (Supplemental
Material, Fig. S10).
Interestingly, at early disease stages, mutation in hsf-1
caused a more severe effect on AT3q130 aggregation, when
compared with daf-16. Quantification of the aggregates (42)
at day 1 revealed that the absence of HSF-1 significantly
increased the percentage number of aggregates per total area
when compared with daf-16; AT3q130 and AT3q130
animals (#P, 0.05, Fig. 7F). Moreover, quantification of the
aggregates in specific areas of the nervous system revealed
that total body aggregation correlates with aggregation in the
animals head (nerve ring and head processes) and in the
VNC (Supplemental Material, Fig. S11). Both total body
aggregation (Fig. 7F) and neuron-specific aggregation (Sup-
plemental Material, Fig. S12) are modified by IIS and HSF-1.
Taken together, these results demonstrate that ATXN3 pro-
teotoxicity is strongly modulated by aging-related cellular
changes, associated with the IIS pathway and the HSR.
DISCUSSION
We describe a new model system for human ATXN3 proteo-
toxicity in C. elegans neuronal cells, in which the use of
tissue-specific promoters and the ability to monitor the fluor-
escence of reporter proteins in different neurons of live
animals (by microscopy and dynamic imaging analysis) pro-
vides an effective means to continuously evaluate mutant
ATXN3 aggregation and pathogenesis. We have taken advan-
tage of the single-cell resolution of the FRAP analysis to scru-
tinize the solubility of ATXN3 in specific neuronal subtypes.
In C. elegans, ATXN3-flanking sequences greatly modulate
polyQ-mediated aggregation and neuronal dysfunction. The
neuronal cell-type-specific susceptibility to expression of
mutant ATXN3 proteins is not stochastic and differs signifi-
cantly from that of polyQ-alone. We also show that mutant
ATXN3 phenotypes are severely aggravated during aging
and demonstrate the protective roles of the DAF-16 and
HSF-1 pathways to suppress proteotoxicity.
Caenorhabditis elegans model for ATXN3 aggregation
and neuronal dysfunction
In our C. elegans model, we observed the polyQ length-
dependent aggregation of both full-length and C-terminal ver-
sions of mutant ATXN3 proteins expressed in C. elegans.
Although ataxin-3 cleavage-fragment formation has not been
unequivocally shown in vivo, many laboratories have proposed
that smaller fragments containing the expanded polyQ
sequence exhibit enhanced toxicity (25,38,40,41,52). Like-
wise, we show the importance of sequence context in that
expression of 75 Qs leads to the formation of protein aggre-
gates in the C. elegans nervous system within C-terminal
ATXN3 flanking regions, but not in the full-length protein.
This is likely due to the increased exposure of the polyQ
tract in the truncated version of the protein, which eventually
facilitates (i) misfolding and (ii) abnormal toxic interactions in
the cellular environment of the affected neurons. There are
several lines of evidence that support this hypothesis,
namely that Q40 has been described as the Q-length threshold
for aggregation and toxicity (32). Moreover, the majority of
studies using cell lines, Drosophila and mouse models of
MJD showed stronger phenotypes with truncated
polyQ-containing versions of ATXN3 (24,41,53); in some
cases, the full-length mutant ATXN3 did not cause pathogen-
esis (41,53). Regarding potential abnormal toxic interactions
in the affected cellular environment, it has been reported
that the presence of an expanded polyQ tract facilitates and
strengthens the interaction between the C-terminal of
ATXN3 and VCP (54), CBP and the transcriptional
co-activators p300 and pCAF (55). These abnormal inter-
actions may affect basic cellular maintenance mechanisms
such as endoplasmic reticulum-associated protein degradation
(56) and transcriptional regulation (55,57).
ATXN3-flanking sequences and cell-intrinsic factors may
direct neuronal cell-type-specific susceptibility
Each of the polyQ disorders involves the loss of selected popu-
lations of neurons, leading to a characteristic clinical presen-
tation, even though the mutant proteins are ubiquitously
expressed (6). As in the human disease, we found that the
neuronal cell-type susceptibility to mutant ATXN3 protein
aggregation and toxicity in the C. elegans nervous system
was not stochastic, but was rather neuron-type-specific and
observed in multiple animals and transgenic lines.
A key finding here is that the aggregation pattern of
ATXN3- and polyQ-expressing animals is quite distinct.
Mutant ataxin-3 aggregates in several neuronal processes,
including commissures, the DNC and sensory processes. In
particular, the processes of certain CHE-13-positive sensory
neurons contain protein foci only when the polyQ tract is
expressed within ATXN3-flanking sequences and not when
expressed alone (32). Although the cell bodies of lateral
neurons contained soluble ataxin-3 proteins, even in very old
animals, their processes often presented aggregates as
Figure 7. IIS and HSF-1 pathways regulated mutant ataxin-3-mediated proteotoxicity inC. elegans neurons. (A) Flattened z-series of AT3q130 and daf-2; AT3q130
animals that were grown at 158C for 4 days and transferred to 208C for 24 h. (B–E) Animals were grown at 208C during their lifespan. White squares highlight the area
where the decrease in aggregation is most clear. (A, B andF) daf-2(e1370) and age-1(hx546)mutations tend to reduce AT3q130-mediated aggregation. The absence
of DAF-16 (D) and HSF-1 (E) increased aggregation of mutant ATXN3 (F). The daf-16(mu86) mutation caused a mild aggravation of the aggregation phenotype,
visible at day 3 (post-hatching) (D, square). hsf-1(sy441) (E) mutation had a great impact on aggregation, with some aggregates visible already in embryos (arrow).
Scale bar, 50 mm. All pictures were obtained using an Olympus FV1000 confocal microscope. (F) Quantification of the number of aggregates per area of animal of all
strains. Data show the mean+SD of eight or more animals. Asterisk indicates the significant mean difference between either hsf-1; AT3q130 or daf-16; AT3q130
and AT3q130 animals; hash symbol indicates the significant difference between hsf-1; AT3q130 and daf-16; AT3q130 (ANOVA, applyingBonferroni correction with
95% confidence intervals; ∗ ,#P , 0.05). (G and H) daf-2 and age-1 mutations reduced the percentage of motor dysfunction (from 46.8 to 25.6% and 40 to 14.7%
reduction, respectively). daf-16 and hsf-1mutations caused an increase in the % of locomotion defective animals (from 40.1 to 74.4% and 40.1 to 100%, respectively).
Data are the mean+SD, at least 102 animals per data point. Student’s t-test, ∗P, 0.05.
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determined by FRAP. By comparison, these processes were
unaffected in Q40 animals (32). In agreement with these
observations, a recent systematic immunohistochemical analy-
sis of serial thick brain sections of MJD patients revealed the
widespread presence of axonal aggregates in fiber tracts
known to undergo neurodegeneration (58). This may be
related to the protein cellular function since the josephin
domain of ATXN3 was found to bind to alpha- and beta-
tubulin in human cells and rat brain extracts (59,60) and that
ATXN3 knock-down led to cytoskeletal disorganization
(59). These results imply that ATXN3-flanking sequences,
other than the polyQ stretch, in conjunction with cell-specific
factors, may modulate neuronal vulnerability.
Recent studies have suggested that the specific symptoms of
a given misfolding disorder, namely ALSQ4 , may not be due
solely to aggregation-mediated toxicity of SOD1 mutations,
but also to their genetic interactions with mildly destabilizing
missense temperature-sensitive alleles within a variety of cel-
lular pathways (61). Studies in HD have also identified the
small G protein Rhes, which is expressed and localized very
selectively to the striatum, as an interactor of mutant hunting-
tin, contributing to cytotoxicity (62). These studies, together
with our results, emphasize the importance of understanding
the role of protein context in diseases characterized by
protein aggregation.
Intriguingly, in both full-length and truncated ATXN3
models, the same neurons were affected, although at different
ages or polyQ lengths. The fact that we have observed similar
neuropathology in animals expressing the ATXN3 cleavage
fragment lends support to the relevance of ataxin-3 fragment
formation in MJD pathogenesis. However, additional exper-
iments are required to determine the protein domain(s) of
ATXN3 that determine the neuronal specificity of
polyQ-mediated pathogenesis.
IIS- and HSF-1-mediated improved proteostasis protect
against mutant ataxin-3 pathogenesis
Aging is a prominent determinant of the structural and func-
tional changes that may contribute to the decline in brain func-
tion and susceptibility to neurodegenerative disease (63). The
age-related IIS and HSF-1 pathway(s) are known to modulate
many forms of toxic protein aggregation in C. elegans and
other model organisms, including the aggregation of Ab
(22,64), a-synuclein (65,66), polyQ and huntingtin
(20,36,67), suggesting that these pathways correspond to a
common mechanism of detoxification. However, for MJD,
the roles of the IIS and HSF-1 pathways had not been pre-
viously examined. In this study, we have shown that aging
intensifies mutant ATXN3 aggregation and motor dysfunction.
Moreover, neuronal toxicity was significantly affected by
altering the aging/survival program. Specifically, DAF-16
and HSF-1 were found to be potent suppressors of mutant
ataxin-3 aggregation and neuronal dysfunction in C. elegans.
The absence of HSF-1 accelerated aggregation at early
stages of development (embryos), whereas in a daf-16
mutant, increased aggregation was more pronounced in adult
animals. In agreement, VA-treated animals showed reduced
aggregation and motor dysfunction later in life (day 10),
which was dependent upon DAF-16. Aggregate quantification
in day 1 animals further supported this finding, as we also
showed that mutant ATXN3 aggregation was greatly enhanced
by the hsf-1 mutation compared with daf-16. This supports the
proposal that HSF-1 and DAF-16 have different developmen-
tal requirements—early embryonic for HSF-1 versus adult for
DAF-16—in protection against proteotoxicity as observed pre-
viously in a C. elegans model for AD Q4(68). In future studies,
we aim to test whether the effects of DAF-16 and HSF-1
loss of function in mutant ATXN3-mediated pathogenesis
are due to neuronal effects.
Figure 8. Pharmacological activation of DAF-16 and HSF-1 reduced mutant ataxin-3-mediated pathogenesis. VA-treated AT3q130 animals showed a reduction
both in motor dysfunction (71.75% to 37.9% reduction in locomotion defective animals) (A) and in the aggregation phenotype at day 10 of adulthood (B).
Despite the broad actions of VA, the effect on ATXN3 pathogenesis seemed to be highly dependent on DAF-16 (A). Day 4 animals treated with two concen-
trations of 17-DMAG also improved their motility performance. The effect of 17-DMAG on motor function was dependent on hsf-1 (C). Animals also showed a
reduction in aggregation (D). Motility data are the mean+SD, at least 152 animals per data point. Student’s t-test, ∗P, 0.05. Quantification of number of
aggregates per area is the mean+SD of eight or more animals per group. ANOVA, ∗P , 0.05.
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Transcriptomes regulated by DAF-16 and HSF-1 include
mRNAs for many chaperones (20,21). In this sense, our
results are in agreement with studies showing that, in the
brain tissue of MJD patients, Hsp40 and Hsp70 localize to
intranuclear aggregates (possibly causing a depletion of
these chaperones) and that overexpression of the human
DnaJ homolog (Hdj)-1 suppressed ATXN3 aggregation and
toxicity in neuronal cell cultures (69). Moreover, knocking
out the co-chaperone C-terminus of Hsp70-interacting
protein enhanced ataxin-3 aggregation-mediated toxicity
(70). Consistent with our results using a genetic approach,
pharmacological treatment with 17-DMAG reduced
mutant-ATXN3 proteotoxicity in C. elegans, probably by acti-
vating the disaggregation capacity of HSF-1 at early stages of
the disease (22,68).
In conclusion, our study supports a link between lifespan
determinants, integrity of protein folding and amelioration of
aggregation-associated proteotoxicity in MJD. Our novel C.
elegans ATXN3 pathogenesis model may constitute a useful
tool for high-throughput testing of therapeutic strategies in
age-related conformational disorders. Additionally, compari-
son of our system with the previously established polyQ
protein-alone models and with C. elegans models for the
pathogenesis of the different disease-associated proteins (hun-
tingtin, androgen receptor or ataxin-1) could allow the clarifi-
cation of both common and protein-specific mechanism(s) of
aggregation, neuronal dysfunction and neurodegeneration.
MATERIALS AND METHODS
Plasmid constructs
Pan-neuronal ATXN3 expression was achieved by cloning
AT3var1–1 cDNA into the PF25B3.3Q0::YFP plasmid (32).
F25B3.3::GFP is a post-mitotic pan-neuronal marker; its
expression is observed after the terminal division of neurons
and not in neuroblasts (37). Full-length ATXN3 cDNA with
different polyQ lengths was generated by PCR using oligonu-
cleotides containing restriction sites for BamHI and
pBluescriptIISK(+)::MJD1–1q14 or pGEM-7Zf(+)::MJD1–
1q75 (kindly provided by Dr Jun Goto) as templates.
ATXN3 amplicons were then digested and ligated into the
BamHI sites of PF25B3.3Q0::YFP, generating PF25B3.3AT3v1–
1q(n)::YFP. Regarding the cloning of PF25B3.3AT3v1–
1q(130)::YFP, the first step was to subclone the tract of
130Qs from pPD95.77::Punc119::MJD1–130Q (kindly pro-
vided by Dr N. Nukina) into the BglII and Eco0109I restriction
sites of pGEM-7Zf(+)::MJD1–1q75 vector. ATXN3 C-
terminal YFP-tagged expression constructs were generated
by PCR (using full-length constructs as a template) and
cloned into the BamHI sites of PF25B3.3Q0::YFP, forming
PF25B3.3257cAT3q(n)::YFP. Sequencing confirmed the
ATXN3 sequence (full-length and truncated forms), including
the Q-length and YFP sequences, as well as the promoter
region.
Nematode strains and general methods
For a list of strains used in this work and name abbreviations,
see Supplementary Material, Table S1. Standard methods were
used for culturing and observing C. elegans, unless otherwise
noted (71). Nematodes were grown on NGM plates seeded
with Escherichia coli OP50 strain at 208C. All strains carrying
the daf-2 mutation (e1370 allele) were grown at 158C until the
L4 stage and were then transferred to 208C for 24 h. For the
generation of transgenic neuronal animals, 50 ng/ml21 of
DNA encoding PF25B3.3AT3q(n)::YFP and PF25B3.3257-
cAT3q(n)::YFP was microinjected into the gonads of adult
hermaphrodite N2 animals, as previously reported (32). Trans-
genic F1 progeny were selected on the basis of neuronal fluor-
escence. At least three independent stable lines for each
transgene were isolated and analyzed, with similar results.
Transgenic lines were frozen immediately after they were gen-
erated, as it has been previously reported that animals kept in
continuous culture, particularly those expressing expanded
polyQ tracts, eventually adapt to the transgene (72). Integrated
lines were generated by gamma irradiation of transgenic
animals expressing AT3q(n)::YFP and 257cAT3q(n)::YFP
fusion proteins, allowing uniform expression of transgenes.
Two or three independent lines were isolated and backcrossed
at least five times with N2. PCHE-13::mCherry DNA (PS431,
kindly provided by Peter Swoboda, Karolinska Institute) was
microinjected into adult hermaphrodite AT3q130 animals at
10 ng/ml21. Populations were synchronized either by treating
young adult animals with alkaline hypochlorite solution
(0.5 M NaOH, 2.6% NaClO) for 7 min (73) or by collecting
embryos laid by adult animals within a 3 h period. All animals
were scored at the same chronological age, unless stated other-
wise. During the reproductive period, animals were moved
every day to avoid progeny contamination. Experiments
were repeated at least three times. All assays were performed
blind.
Confocal imaging
All images were captured either on a Zeiss LSM510 META
(Oberkochen, Germany) or on an Olympus FV1000 (Japan)
confocal microscope, under a 63× water or 60× oil objective,
respectively. Animals were immobilized with 2 mM levami-
sole and mounted on a 3% agarose pad. Z-series imaging
was taken of all the C. elegans lines generated, using 514/
515 nm laser excitation for YFP, 458 nm for CFP and
593 nm for mCherry fusion proteins. The pinhole was adjusted
to 1.0 Airy unit of optical slice, and a scan was taken every
0.5 mm along the Z-axis. Immobilized 4- or 10-day-old
animals were subjected to FRAP as previously described
(74) with the following modifications: imaging of full-length,
C-terminal ATXN3 and ATXN3;Q40 animals was performed
at 5% power of a 514 nm laser line with the bleaching power
of 100% for 25 iterations. Relative fluorescence intensity
(RFI) was determined using the following equation: RFI ¼
(Tt/Ct)/(T0/C0), in which T0 is the total intensity of the
region of interest (ROI) prior to photobleaching and Tt is
the intensity of the same area at a given time after bleaching.
The intensities were normalized against a non-bleached ROI
within the same cell (C0, intensity of the control area prior
to bleaching and Ct at any time after) as a control for
general photobleaching and background fluorescence (74).
FRAP analysis was consistently performed in all animals in
at least six VNC (adjoining the vulva), DNC (opposing the
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vulva) cells, head neurons and tail neurons (cell bodies and/or
processes). FRAP of HSN neurons was performed on an
Olympus FV1000 confocal microscope (1% power of a
515 nm laser line with bleaching power of 50%, using the
Tornado scanning mode).
Quantification of the aggregates
Caenorhabditis elegans fluorescent images were acquired
using the Olympus FV1000 confocal microscope. Confocal
microscope parameters were set using Hi-Lo pallet, such
that protein foci and not diffuse fluorescent areas of the
animals nervous system presented pixel intensity higher than
255. The z-stack was collapsed and the aggregate load of
each animal (per area unit) was calculated on an image-
processing application using MeVisLab as a platform.
Details on the application and on the segmentation algorithms
were described elsewhere (42). At least eight images were
analyzed per genotype and statistical assessment was per-
formed using the Origin software (OriginLab) (ANOVA and
Bonferroni mean correction tests for multiple comparisons).
Motility assay
All assays were performed at room temperature (208C)
using synchronized animals grown at 158C or 208C. Five
animals (4-, 5- or 10-day-old) were placed simultaneously in
the middle of a freshly seeded plate, equilibrated at 208C.
Animals remaining inside a 1 cm circle after 1 min were
scored as locomotion-defective. A total of 150 animals were
scored in at least three independent assays for each strain,
and the statistical significance was assessed by Student’s
t-test, as described previously (44).
VA treatment
VA treatment was performed according to the protocol
described by Evason et al. (50). VA sodium salt was obtained
from Sigma (St Louis, MO, USA). Animals were always
grown in 6 mM VA plates at least one generation prior to the
beginning of the assay and were kept in the dark. After 10
days (post-hatching), animals were scored for motility
defects and alteration in the aggregation profile, using confo-
cal imaging.
17-DMAG treatment
Drug assays were performed in 96-well plates in liquid
culture, as previously described (43,75). Each well contained
a final volume of 60 ml, including 20–25 animals in egg
stage, drug at the appropriate concentration and OP50 bacteria
to a final OD of 0.8 in the microtiter plate (Bio-Rad). Animals
and bacteria were resuspended in S-medium supplemented
with streptomycin, penicillin and nystatin (Sigma). Worms
were grown with continuous shaking at 180 rpmQ5 at 208C.
Compound preparation: a stock solution of 16.2 mM
17-DMAG (NCS707545, InvivoGen) was prepared in water.
On the indicated days, animals were imaged using a confocal
microscope (Olympus FV1000) and tested for motility defects.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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